📋 Browse Articles

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
Filtered by: CLN3 ✕ clear all
🏷️ Tags (31969 usages)
📦 Other 1510
▸ Other (850)
brain-derived neurotrophic factor (39)neuroplasticity (32)exercise (20)neurobiology (19)neurotoxicity (18)trkb (16)traditional chinese medicine (15)genetics (15)neurotrophic factors (14)hippocampal (13)central nervous system (12)neuroprotective (11)gut-brain axis (10)neurology (10)stroke (10)obesity (9)neurotrophic (9)psychology (9)dementia (9)zebrafish (8)bipolar disorder (8)neurotrophins (8)blood-brain barrier (8)aging (7)anti-inflammatory (7)neuropsychiatric disorders (7)memory (7)nanoparticles (7)neuropathic pain (7)neurotransmission (6)neurological disorders (6)mental health (6)neurotrophin (6)rats (6)stem cells (6)neuromodulation (6)astrocytes (6)neurodevelopmental disorders (6)psychiatry (6)cns (5)neuronal cells (5)meta-analysis (5)bioavailability (5)biochemistry (5)pathology (5)psychedelics (5)probiotics (5)amyloid-β (5)epilepsy (5)neurodevelopment (5)polymorphism (5)akt (5)aerobic exercise (5)astrocyte (4)nutrition (4)metabolomics (4)toxicity (4)neuroimmune (4)amyloid beta (4)myokines (4)brain health (4)rat model (4)physical exercise (4)neurotransmitter (4)ischemic stroke (4)neuropathology (4)physical activity (4)ngf (4)mesenchymal stem cells (4)neurodevelopmental disorder (4)physiological (3)overactive bladder (3)neuroblastoma (3)amyloid-beta (3)pathophysiology (3)extracellular vesicles (3)immune cells (3)microbiota (3)pi3k (3)neurotransmitters (3)pain management (3)camp (3)il-6 (3)neuronal survival (3)erk (3)hypoxia (3)interleukin-6 (3)estrogen (3)amyloid (3)neural development (3)intervention (3)neurobehavioral (3)voiding dysfunction (3)bioinformatics (3)metabolic (3)immunomodulation (3)ischemia (3)mitophagy (3)long-term potentiation (3)extracellular matrix (3)chemotherapy (3)brain function (3)psilocybin (3)microbiome (3)neuroendocrine (3)endocrine (3)cytokines (3)mouse model (3)neuropsychiatric (3)gastrointestinal (3)psychiatric disorders (3)sciatic nerve injury (3)anxiety disorders (3)hyperlipidemia (3)neurobiological (3)nerve growth factor (2)neuronal function (2)developmental toxicity (2)neural (2)gut health (2)biological (2)immunology (2)camkii (2)excitotoxicity (2)electrophysiological (2)urinary biomarkers (2)val66met polymorphism (2)behavioral (2)neuronal development (2)sleep deprivation (2)alpha-synuclein (2)neurological deficits (2)neuropsychiatry (2)empagliflozin (2)p2x4r (2)psychiatric disorder (2)cytokine (2)physiology (2)polyphenol (2)western diet (2)amnesia (2)calcium (2)multi-omics (2)gene therapy (2)neural stem cells (2)magnetic stimulation (2)exercise interventions (2)generalized anxiety disorder (2)serotonergic (2)yoga (2)microglial polarization (2)ischemic brain injury (2)mdd (2)in vivo (2)suicide (2)pathogenesis (2)anesthesia (2)cell death (2)substance use disorders (2)skeletal muscle (2)lead (2)radiotherapy (2)cardiology (2)5-ht (2)lactate (2)lipopolysaccharide (2)inflammatory (2)intermittent fasting (2)brain-gut axis (2)microgravity (2)mindfulness (2)hippocampal bdnf (2)hypertension (2)immunomodulatory (2)flavonoid (2)bone marrow (2)polyunsaturated fatty acids (2)ganoderma lucidum (2)pain (2)high-fat diet (2)gsk-3β (2)tissue engineering (2)adhd (2)il-10 (2)ampk (2)pink1 (2)microglial activation (2)muscle atrophy (2)amplitude (2)peripheral neuropathy (2)tissue plasminogen activator (2)metabolic health (2)healthy aging (2)wild (1)protein kinase (1)pesticide (1)brain abnormalities (1)immune (1)neural health (1)apoe (1)plant-based (1)cellular models (1)neurodevelopmental trajectories (1)synthesis (1)neurobehavioral toxicity (1)cas9 (1)histology (1)electrical stimulation (1)microglial dysfunction (1)hippocampal neurogenesis (1)plasticity (1)glutamatergic (1)phytochemical (1)urinary ngf (1)muscle weakness (1)gα (1)probdnf (1)stem cell therapy (1)nogo-a (1)schwann cell (1)diabetic neuropathy (1)blood biomarker (1)memantine (1)gs3kβ pathway (1)akt1 (1)nssi (1)ect (1)matrix metalloproteinases (1)nme3 (1)biology (1)platelet activation (1)whole-body vibration (1)gestation (1)neuronal plasticity (1)brain barriers (1)neurotransmitter systems (1)biomedicine (1)excipient selection (1)misa (1)genetic polymorphism (1)gsк-3β (1)bayesian network meta-analysis (1)addictive behaviors (1)motor neurons (1)chemical (1)tlr4 (1)psychotherapy (1)plga (1)atrazine (1)induced pluripotent stem cells (1)processed products (1)mental illness (1)nr2b (1)dendritic atrophy (1)domestication (1)adverse childhood experiences (1)hydrophobic interior (1)gestational intermittent hypoxia (1)neuropathy (1)calcineurin (1)sepsis-associated brain injury (1)gdnf (1)crispr (1)becn1 (1)appetite (1)derivatives (1)pediatric (1)nanocage (1)fibromyalgia (1)omega-3 fatty acids (1)paroxetine (1)mri (1)methyl donor (1)neuromodulatory (1)embryo development (1)case management (1)brain aging (1)bcl-2 (1)mettl3 (1)htr2c (1)psychological disorders (1)neurite outgrowth (1)erythropoietin (1)mastication (1)proteolytic processing (1)brain distribution (1)methylation (1)mental disorder (1)intestinal flora (1)pet (1)histone deacetylase (1)gut microbiome (1)proteome (1)klotho (1)attention deficit hyperactivity disorder (1)synthetic cannabinoid (1)human health (1)gene (1)metaplasticity (1)pkb (1)neurotherapeutics (1)sciatic nerve ligation (1)play behaviour (1)pediatric motor disorder (1)eeg (1)mood (1)cxcr4 (1)de novo lipogenesis (1)ultrasound (1)psychiatric therapies (1)nf-kappa b (1)excitatory synapses (1)hap1 (1)therapy (1)il6 (1)neat1 (1)pppar (1)surgical management (1)biochemical role (1)interleukins (1)agrochemical (1)calcium channels (1)neuronal activation (1)protein (1)pathophenotypes (1)glycation (1)dyspnea (1)genomics (1)epidemiology (1)acetylcholinesterase (1)polymorphic variants (1)thiazole (1)perinatal programming (1)neural pathways (1)degradation (1)uveitis (1)synthetic opioid (1)nanocarriers (1)vitamin d3 (1)metabolic dysfunction (1)astroglia (1)pparα (1)pfas (1)glial cells (1)ace2 (1)muscle (1)network (1)uhplc-q-tof-ms/ms (1)sglt2 inhibitor (1)biological aging (1)biochemical analysis (1)astrobiology (1)microbiota-gut-brain axis (1)local translation (1)wharton's jelly (1)essential oil (1)upper motor neuron (1)vulnerability (1)visceral pain (1)adolescence (1)histological damage (1)amyk (1)systemic (1)neural alterations (1)maoa (1)neuroprotectants (1)metabolic flexibility (1)polycystic ovary syndrome (1)neuroprotectors (1)trk (1)genotype (1)migration (1)brain metastases (1)jak2 (1)neuron-microglia interactions (1)behavioral disorders (1)hsd10 (1)aging brain (1)neurotoxicants (1)cell biology (1)neurological function (1)pkr inhibition (1)mict (1)antipsychotic (1)child mental disorder (1)blood brain barrier (1)stat3 (1)ipsc-derived neurons (1)cannabis (1)sepsis-associated encephalopathy (1)functional (1)olfaction (1)protein design (1)neurons (1)genetic background (1)axon growth (1)metformin (1)atf4 (1)blood-based biomarkers (1)multisystem (1)neutrophil extracellular traps (1)cd4 (1)phenolic acid (1)tissue inhibitors of metalloproteinases (1)inflammasome (1)obstetrics (1)fat oxidation (1)ondansetron (1)physical function (1)ipsc (1)ythdf1 (1)glymphatic function (1)immune system (1)nutritional strategies (1)anesthetics (1)ich (1)electroencephalogram (1)rodent models (1)in vivo study (1)phthalates (1)physiotherapy (1)nlrp3 (1)electroporation (1)older adults (1)sexual dysfunction (1)mice (1)sesquiterpenoid (1)fibrinolytic (1)gut-brain interactions (1)n-acetylcysteine (1)body weight (1)mfn2 (1)rat brain (1)hiit (1)inflammatory process (1)spinal disc (1)pacap (1)opioid use (1)ayahuasca (1)genetic risk factor (1)pkc delta (1)endothelial cells (1)lactation (1)hepatocellular carcinoma (1)cell viability (1)necrotic cell death (1)offspring behavior (1)cholinergic dysfunction (1)neurobiomarkers (1)neurotrophin-3 (1)canagliflozin (1)anxiety disorder (1)orthopedic fixation (1)neurodevelopmental biology (1)fragile x syndrome (1)npas4 (1)mesoporous silica (1)cardioprotective (1)hydrocephalus (1)neurological disorder (1)microbiomics (1)nanotherapeutics (1)tubulin (1)neuroinflammatory signalling (1)sineup (1)p75ntr (1)8-iso-pgf2α (1)diabetic neuropathic pain (1)lumbrokinase (1)nlrp3 inflammasome (1)neural organoid (1)neurobiochemistry (1)photoplethysmography (1)cadmium (1)fibroblast-growth factor-21 (1)bulimia (1)calcium-binding protein (1)nursing intervention (1)lipid rafts (1)hallucinogens (1)immune checkpoint (1)trka (1)biological markers (1)social interaction (1)systemic inflammation (1)passive smoking (1)atp production (1)nad (1)biological pathways (1)endocrine disorder (1)decline (1)anxiolytic (1)translation (1)kinases (1)personalized medicine (1)protein formulation (1)vagus nerve (1)carbon dots (1)aerobic (1)in vivo efficacy (1)polyphenols (1)motivational behaviors (1)gonadal hormones (1)nanotechnology (1)neurological growth (1)mitogen-activated protein kinase (1)cannabidiol (1)neuronal degeneration (1)oxidative damage (1)public health (1)radiation-induced brain injury (1)cholinergic (1)therapeutics (1)meditation (1)salmon (1)gut brain axis (1)chemokines (1)toxoplasma gondii (1)omics (1)bdnf/trkb pathway (1)neuroanatomy (1)hepatoprotective (1)nanofibers (1)growth factor (1)dietary triglyceride (1)eating behavior (1)tgf-β (1)homing (1)neuropsychology (1)visual stimulation (1)histone (1)t cells (1)diabetic ischemic brain injury (1)bax (1)behavioral performance (1)prkn (1)metabolic alterations (1)stem cell (1)axon guidance (1)sumoylation (1)acd (1)erbb4 inhibitor (1)two-hit model (1)perk (1)tug1 (1)gene activation (1)tea polyphenols (1)tcm (1)developmental neurotoxicity (1)hormonal (1)plasmin (1)emotion axis (1)bdnf pathway (1)mmp-9 (1)heavy metal (1)histologic analysis (1)platelet factor 4 (1)fisetin (1)neurobehavioral deficits (1)anaerobic exercise (1)hypoxanthine (1)motor function (1)hippocampal neurons (1)psychedelic (1)nutritional psychiatry (1)nerve injury (1)brain-derived neurotrophic factors (1)behaviors (1)mct oil (1)hippocampal plasticity (1)hippocampal development (1)kcc2 (1)peripheral blood mononuclear cells (1)ecb (1)pcl (1)exercise intervention (1)glial scarring (1)ovine (1)lung-brain axis (1)hyperventilation syndrome (1)hbv (1)endocannabinoid pathways (1)geriatrics (1)neonatal brain proteomics (1)muscle pain (1)etiology (1)weightlessness (1)biodegradable materials (1)ho-1 (1)pain subtypes (1)cxcl12 (1)bdnf signalling (1)p2x7r (1)salivary gland (1)cholesterol (1)vitamin d (1)behavior (1)nmda (1)genetic (1)sociodemographic factors (1)neuroprotective properties (1)ethanol (1)oral delivery (1)suicidal ideation (1)neurophysiology (1)synovial fibroblasts (1)translational (1)bioactivity (1)function (1)neural stimulation (1)muscle function (1)ophthalmology (1)gene-tbi interactions (1)macrophages (1)cannabinoid (1)fatty acids (1)piezoelectric (1)tms (1)hepatic encephalopathy (1)mood disorders (1)tph2 (1)cardiometabolic disease (1)psychological (1)single-nucleotide variants (1)schwann cells (1)euglena gracilis (1)inflammatory bowel disease (1)intestinal barrier (1)emotional disorders (1)hyperammonemia (1)5-ht pathway (1)app (1)sleep (1)olfactory system (1)neurovegetative (1)beta-glucan (1)lithium chloride (1)psychobiotics (1)brainstem (1)neuronal growth (1)glioma (1)apolipoprotein e (1)psychotropic (1)substance use disorder (1)neurobiological alterations (1)dendritic morphology (1)b-cell lymphoma 2 (1)puberty (1)cmd (1)electromagnetic field (1)neurochemicals (1)pgc1α (1)low back pain (1)dheas (1)biological sciences (1)intranasal delivery (1)neurotrophic hypothesis (1)cbt (1)sik1 (1)magnetically targeted (1)motor neuron disease (1)visceral hypersensitivity (1)psychiatric genetics (1)drp1 (1)butyrate (1)six3 (1)triclocarban (1)proteomic clustering (1)pharmaceutical (1)cellular nerve damage (1)parkin (1)sciatic nerve (1)pediatrics (1)sepsis (1)pcr (1)traditional uyghur medicine (1)murine model (1)bace1 (1)liquid crystalline (1)gwas (1)neuroblastoma cells (1)signalling pathway (1)brain oxygenation (1)paxillin (1)inflammatory markers (1)neural damage (1)mass spectrometry (1)sleep-promoting (1)monocytes (1)mh (1)sex hormones (1)brain biomarkers (1)immune activation (1)glutamatergic system (1)akt pathway (1)pituitary gland (1)neurochemistry (1)phytochemical analysis (1)plant (1)behavioral deficits (1)tnfα (1)psychiatric (1)peripheral nerve injury (1)clearance system (1)acrylamide (1)behavioral dysfunction (1)gut-hippocampus axis (1)neonatal development (1)vitamin c (1)ppparα (1)uflc-q-tof-ms/ms (1)stagnant phlegm syndrome (1)neurodelivery (1)cav1 (1)metabolic processes (1)gpr40 (1)na/k-atpase (1)nuclear translocation (1)nanoemulsion (1)pericytes (1)p2y1r (1)next-generation sequencing (1)neuroactive lignan (1)food intake (1)neuronal injury (1)muscle denervation (1)inflammatory pathways (1)sox5 (1)herbicide (1)neuroma (1)maya-mestizo population (1)dexras1 (1)msc (1)microcystin (1)amyloid plaque (1)cardiometabolic (1)rat models (1)val66met (1)rock1 (1)plasma technology (1)statins (1)bdnf-trkb pathway (1)mendelian randomization (1)protein kinase b (1)neural plasticity (1)oxidative balance (1)spleen-kidney deficiency (1)prisma (1)metabolic function (1)proinflammatory cytokines (1)antioxidative (1)multiple system atrophy (1)neurobehavior (1)mcao (1)herbal medicine (1)eating disorders (1)brain plasticity (1)hyperglycemia (1)visual function (1)peripheral brain-derived neurotrophic factor (1)lithium (1)dry eye model (1)hepatocyte (1)tnf-α (1)proteases (1)neurological health (1)steroid hormones (1)dendritic spine (1)uhplc-qtof-ms (1)social memory (1)perineuronal networks (1)phytoestrogen (1)childhood obesity (1)lc-ms (1)microvesicles (1)caspase-4 (1)inflammaging (1)muscle-brain axis (1)spions (1)therapeutic implications (1)adolescent brain (1)rotenone (1)metabolic syndrome (1)no (1)lineage (1)neural network (1)phq-9 (1)lipid-lowering (1)gene mutations (1)biochemical (1)pka (1)central sensitization (1)matrix metalloproteases (1)risperidone (1)morphological deficits (1)panax ginseng (1)bioprinted (1)neurotoxicity-associated metabolic alterations (1)polymorphisms (1)minocycline (1)ntrk (1)lcn2 (1)behavioral science (1)liver injury (1)pituitary (1)biophysics (1)cholinergic function (1)orthopedics (1)neural tissue (1)hippocampal injury (1)gastric ulcer (1)vitality (1)space medicine (1)igf-1 (1)intrinsic capacity (1)central nervous system disorders (1)neurodevelopmental studies (1)single-nucleotide polymorphisms (1)fasd (1)polygalae radix (1)exerkines (1)pathophysiological interactions (1)walking (1)chemobrain (1)neural function (1)ingestion (1)bangladeshi population (1)urodynamics (1)aβ plaques (1)immuno-modulation (1)pathway (1)neuroendocrinology (1)supplementation (1)brain tissue (1)cardiotoxicity (1)mglur5 (1)acetylation (1)microplastic (1)therapeutic perspectives (1)methylxanthine (1)naphthoquinone (1)myokine (1)analgesia (1)gst (1)choroid plexus (1)plasma biomarkers (1)glutamatergic pathways (1)biomaterials (1)global health (1)inhibitor (1)
⚗️ Metals 1041
▸ Metals — Other (620)
neuroscience (64)cognitive function (30)synaptic plasticity (25)stress (15)antidepressant (14)pharmacology (11)cognitive dysfunction (10)toxicology (9)cognition (9)serotonin (8)major depressive disorder (7)molecular biology (7)spinal cord injury (7)prefrontal cortex (7)chronic stress (6)autism spectrum disorder (6)chronic pain (6)exosomes (6)ptsd (6)cognitive (6)irisin (5)pregnancy (5)memory impairment (5)network pharmacology (5)cognitive performance (5)endoplasmic reticulum stress (5)neuropharmacology (5)environmental enrichment (4)homeostasis (4)oncology (4)neuroprotective effects (4)traumatic brain injury (4)molecular mechanisms (4)depressive disorder (4)cardiovascular (4)psychopharmacology (4)neuroregeneration (4)resveratrol (4)post-traumatic stress disorder (4)chitosan (4)affective disorders (3)osteoporosis (3)insomnia (3)high-intensity interval training (3)neurobiological mechanisms (3)serum (3)treatment-resistant depression (3)mirna (3)nerve regeneration (3)animal model (3)transcriptomics (3)acupuncture (3)sarcopenia (3)molecular dynamics (3)molecular (3)molecular docking (3)autism (3)rehabilitation (3)electroconvulsive therapy (3)regenerative medicine (3)bioactive compounds (3)prenatal stress (3)melatonin (3)cums (2)tau protein (2)cancer progression (2)er stress (2)glucocorticoid receptor (2)insulin resistance (2)preclinical (2)metabolic regulation (2)quality of life (2)docosahexaenoic acid (2)pharmacogenomics (2)neuroprotective mechanisms (2)gene regulation (2)heart failure (2)alcohol consumption (2)amyotrophic lateral sclerosis (2)ketogenic diet (2)neural circuitry (2)antidepressants (2)trauma (2)retina (2)neurovascular (2)mir-34a-5p (2)ginsenosides (2)stroke recovery (2)transcriptome (2)transcranial magnetic stimulation (2)systematic review (2)molecular pathways (2)regulatory mechanisms (2)executive function (2)postoperative care (2)neuroprotective effect (2)corticosterone (2)post-stroke depression (2)retinal ganglion cells (2)premature ejaculation (2)cognitive recovery (2)selenium (2)learning (2)pharmacological (2)glucagon-like peptide-1 (2)functional recovery (2)circadian rhythms (2)endocrine disruptors (2)early-life stress (2)axonal regeneration (2)naringenin (2)cognitive deficits (2)endoplasmic reticulum (2)alcohol (2)depressive behaviors (2)peripheral nerve regeneration (2)nmda receptor (2)cognitive health (2)cortisol (2)cytoskeleton (2)postoperative cognitive dysfunction (2)infralimbic cortex (2)cerebrum (2)cortical neurons (2)synaptic dysfunction (2)molecular targets (2)benzalkonium chloride (2)prebiotics (2)mild cognitive impairment (2)ethnopharmacology (2)cognitive functions (2)regeneration (2)tau (1)viral infections (1)stress responses (1)physicochemical characterization (1)brain immunity (1)correction (1)retinoic acid (1)post-translational modification (1)exposure (1)lucidenic acid a (1)hepatic steatosis (1)dietary regulation (1)nerve conduits (1)environmental pollutants (1)perigestational opioid exposure (1)meta-regression (1)mechanosensory hair cells (1)hippocampal ca2 region (1)neural precursors (1)photoreceptors (1)anaerobic glycolytic flux (1)respiratory (1)randomized controlled trials (1)ischemic postconditioning (1)molecular changes (1)growth cones (1)total abdominal irradiation (1)cardiovascular disease (1)aggression (1)gold nanoparticles (1)circrna (1)preclinical evidence (1)traumatic injury (1)dopamine d2 receptor (1)progressive (1)psychological trauma (1)drug metabolism (1)neural structure (1)synaptic transmission (1)laquinimod (1)preterm birth (1)resilience (1)peptide design (1)fermented food (1)spatial learning (1)complications (1)allergic contact dermatitis (1)particulate matter (1)corticospinal tract (1)chronic restraint stress (1)cerebellum (1)hepatitis b virus (1)copd (1)post-stroke cognitive impairment (1)tryptophan metabolism (1)ginsenoside (1)auricular vagus nerve stimulation (1)biosynthesis (1)scoping review (1)vascular endothelium (1)opioid prescription (1)mir-381-3p (1)learning-memory (1)fetal alcohol spectrum disorders (1)emotion perception (1)hippocampal structure (1)cell communication (1)sedative-hypnotic effects (1)amniotic fluid stem cell (1)cardiovascular disorders (1)nerve guidance conduits (1)regulatory network (1)synaptic impairment (1)peroxisome proliferator-activated receptor alpha (1)neurocognitive impairment (1)aquatic ecosystems (1)fibronectin type iii domain-containing protein 5 (1)phosphorylated tau (1)oxygen-glucose deprivation (1)chronicity (1)intracerebral hemorrhage (1)osteosarcopenia (1)behavioral responses (1)anorexia (1)selective serotonin reuptake inhibitors (1)stable love relationships (1)psychological treatment (1)hippocampal regeneration (1)redox homeostasis (1)neuroprotective molecules (1)neurovascular plasticity (1)neuropeptide (1)irradiation (1)hemorheological parameters (1)cellular mechanisms (1)cognitive flexibility (1)astrocytic disruption (1)alcohol dependence (1)stroke treatment (1)irritable bowel syndrome (1)seizure susceptibility (1)immune reactions (1)tumor necrosis factor alpha (1)mirnas (1)menopausal (1)microbiota dysbiosis (1)bed rest (1)nicotine (1)bone loss (1)cubosome formulation (1)post traumatic stress disorder (1)vascular dysfunction (1)hyperandrogenism (1)pd-1 (1)hippocampal neuronal apoptosis (1)prenatal exposure (1)pyroptosis (1)withaferin a (1)glycolysis (1)microenvironment (1)redox balance (1)circadian rhythm (1)olfactory exposure (1)nose-to-brain delivery (1)neurocognitive outcomes (1)sex differences (1)neuro-osteogenic microenvironment (1)acute ischemic stroke (1)psychedelic drugs (1)sinomenine (1)secretory protein (1)maladaptive neuroplasticity (1)facial recognition (1)stress disorder (1)carnosine (1)synaptic deficits (1)mir-146a-3p (1)regulation (1)ferritin (1)protein secretion (1)scopolamine-induced amnesia (1)randomized controlled trial (1)principal component analysis (1)appetite regulation (1)psychiatric comorbidities (1)environmental toxicology (1)gynecology (1)hif-1α-epo/camp-creb-bdnf pathway (1)depressive states (1)learning process (1)neural regeneration (1)cardiac arrest (1)psychological outcomes (1)affective states (1)gut dysbiosis (1)long non-coding rnas (1)prefrontal-limbic connectivity (1)psychological reaction (1)extremely low-frequency magnetic field (1)clinical assessment (1)microglial exosomes (1)neurotoxicology (1)epileptogenesis (1)clinical trial (1)anabolic-androgenic steroid (1)ethnic medicine (1)mitochondrial calcium uniporter (1)weight loss (1)amitriptyline (1)stress responsivity (1)serotonergic circuit (1)lps-induced depression (1)locomotion (1)steroidal saponin (1)aquatic organisms (1)correlation (1)drug response (1)transcriptomic (1)long non-coding rna (1)rheumatoid arthritis (1)rem theta (1)absorption (1)chronic heart failure (1)fentanyl administration (1)molecular toxicology (1)vascular cognitive impairment (1)motor impairment (1)adipose-derived stem cells (1)neuro-related disorders (1)emotional regulation (1)restraint stress (1)regenerative capabilities (1)antinociceptive (1)cerebral palsy (1)cerebral infarction (1)normal pressure hydrocephalus (1)positron emission tomography (1)bioengineered delivery system (1)adenosine (1)connexin43 (1)immunoregulation (1)comorbid (1)cerebrovascular disease (1)in silico (1)moderate-intensity continuous training (1)cognitive improvement (1)stress-induced depressive behaviors (1)drug delivery (1)lycopene delivery (1)host-virus interactions (1)phosphatidic acid (1)sirt1 (1)neuroserpin (1)heat stress (1)macular degeneration (1)medial prefrontal cortex (1)intranasal drug delivery (1)early diagnosis (1)rem sleep behavior disorder (1)seizures (1)psychosocial (1)prenatal supplementation (1)adeno-associated virus (1)neurotoxic effects (1)proanthocyanidins (1)neurocognitive (1)anti-inflammatory effects (1)gestational opioid exposure (1)nociceptive sensitization (1)stress axis regulation (1)anthocyanins (1)pruritus (1)phlorotannin (1)high intensity interval training (1)prosopis cineraria (1)psychosis (1)constipation (1)psychedelic compounds (1)delphinidin (1)myostatin (1)triterpenoid saponins (1)limbic structures (1)osteoblast (1)bdnf expression (1)poly(lactic-co-glycolic acid) (1)korean population (1)neuroimmune crosstalk (1)chronic diseases (1)low birthweight (1)α7 nicotinic acetylcholine receptor (1)protein quality control (1)peptide hydrogel (1)fecal calprotectin (1)metabolic adaptation (1)single-cell transcriptomics (1)cell differentiation (1)neurogenic bladder (1)hippocampal synaptic proteins (1)chemoresistance (1)herb pair (1)chronotropic incompetence (1)autism-like behavior (1)testicular health (1)aggressive behavior (1)allodynia (1)obstructive sleep apnea (1)opioid overdose (1)gold coast criteria (1)n-methyl-d-aspartate receptor (1)psychological stress (1)betulinic acid (1)retinal degeneration (1)depressive pathologies (1)traumatic event (1)ros (1)extremely low-frequency electromagnetic field (1)cognitive impairments (1)chronic toxoplasmosis (1)dacomitinib (1)serotonin 5-ht2a receptor (1)pulmonary fibrosis (1)psychostimulant (1)chronic unpredictable mild stress (1)tobacco smoke (1)radiofrequency electromagnetic fields (1)fetal brain development (1)sedative-hypnotic effect (1)social buffering (1)depressive disorders (1)epigenetic dysregulation (1)neuroimmune circuits (1)childhood growth restriction (1)resolvin d1 (1)molecular design (1)glp-1 receptor agonists (1)brain-gut homeostasis (1)neurotrophic adaptation (1)liver failure (1)creb pathway (1)diclofenac (1)n6-methyladenosine (1)immune mechanisms (1)laminin (1)cerebrovascular accidents (1)suicide attempt (1)neural repair (1)synaptic (1)adverse outcome pathway (1)opioid receptors (1)memory impairments (1)fibrotic remodeling (1)neuronal communication (1)appetite control (1)outcomes (1)hypothalamus-pituitary-adrenal axis (1)serum bdnf levels (1)lung homeostasis (1)perioperative neurocognitive disorders (1)cognitive training (1)melatonin receptor (1)adolescent social isolation stress (1)cognitive therapy (1)fear memory (1)osseointegration (1)musculoskeletal system (1)colitis (1)autoimmune uveitis (1)light treatment (1)cerebral protection (1)neurotrophic dysregulation (1)ingredient (1)developmental neurotoxicology (1)transcriptional changes (1)neurosteroids (1)environmental conditions (1)orthostatic hypotension (1)pathological microenvironment (1)autologous serum (1)physiological resilience (1)spatial transcriptomics (1)function recovery (1)age-related macular degeneration (1)seizure (1)mangiferin (1)preclinical models (1)herpes simplex virus (1)exosome-based therapy (1)peptides (1)melanocortin (1)tau phosphorylation (1)tumor necrosis factor (1)eicosapentaenoic acid (1)neural circuit (1)hypothalamic-pituitary-adrenal axis (1)brain structure (1)phosphatidylserine (1)irák1 (1)colorectal cancer (1)perinatal depression (1)learning ability (1)allostatic load (1)adolescent depression (1)creatine supplementation (1)affective dysfunction (1)non-pharmacological interventions (1)personal care products (1)diagnosis (1)unfolded protein response (1)antidepressant mechanisms (1)cerebral hemorrhage (1)autophagic pathway (1)nanocomposite hydrogel (1)causal relationship (1)fear extinction (1)neuropeptide s (1)nociceptive responses (1)dpd-4 inhibitors (1)traumatic stress disorder (1)colon cancer (1)tau hyperphosphorylation (1)tyrosine kinase receptor b (1)ecosystems (1)reproductive physiology (1)stress regulation (1)motor learning (1)disease-syndrome combined model (1)methionine-choline-deficient diet (1)s-nitrosylation (1)neurocognitive disorders (1)postmenopausal women (1)neural recovery (1)kaempferol (1)postoperative delirium (1)receptor (1)social cognition (1)neurocognition (1)environmental (1)hcortisolaemia (1)integrated stress response (1)systemic effects (1)antiretroviral therapy (1)adenosine receptor (1)late-life cognitive decline (1)traumatic memories (1)energy homeostasis (1)antidepressant effect (1)physiological adaptations (1)inflammatory responses (1)tissue architecture (1)vascularization (1)neuroimmune responses (1)human respiratory syncytial virus (1)vision loss (1)rapid antidepressant effects (1)tau pathology (1)drug release (1)signal peptide (1)noncommunicable diseases (1)electrospun (1)alcohol-induced cognitive impairment (1)vasoactive intestinal polypeptide (1)cognitive behavior (1)hypothalamic pituitary adrenal axis (1)machine learning (1)hypothalamic-pituitary adrenal axis (1)parkinsonism (1)cognitive resilience (1)impairment (1)experimental autoimmune uveoretinitis (1)precursor state (1)hmg-coa reductase inhibitors (1)tumor necrosis factor-α (1)relationship (1)cognitive aging (1)clinical psychology (1)antidepressant activity (1)optic nerve injury (1)mechanistic (1)vascular maturation (1)biomechanics (1)aerospace medicine (1)oncogenic drivers (1)differentiation (1)resistance training (1)paraventricular nucleus (1)ecotoxicity (1)synaptic homeostasis (1)environmental concern (1)bdnf/creb pathway (1)creb phosphorylation (1)mood dysregulation (1)nitrous oxide (1)dentate gyrus (1)paternal exposure (1)behavioral despair (1)nicotine exposure (1)lactobacillus plantarum (1)electroacupuncture (1)female mice (1)fetal neural development (1)tropomyosin receptor kinase b (1)environmental contaminants (1)differentiation protocols (1)magnetic resonance imaging (1)reward processing (1)arsenic (1)steroid effects (1)diosgenin (1)stress hormone (1)oral administration (1)hemorheology (1)synaptic models (1)reversal learning (1)synaptic signaling (1)cognitive outcomes (1)presynaptic (1)magnetic field exposure (1)ischemia reperfusion injury (1)nitric oxide (1)toxoplasmosis (1)tyrosine kinase inhibitors (1)acute hepatitis (1)glucagon-like peptide-1 receptor agonists (1)somatosensory cortex (1)serotonin pathway (1)biological effects (1)cyanidin (1)breast cancer (1)
💊 Drugs 4

🔍 Filters

936 articles with selected tags
M Haltia, R Herva, J Suopanki +2 more · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
Epilepsy is a common manifestation in all childhood-onset forms of neuronal ceroid lipofuscinosis. In order to document hippocampal lesions and their relationship to epilepsy we studied autopsy specim Show more
Epilepsy is a common manifestation in all childhood-onset forms of neuronal ceroid lipofuscinosis. In order to document hippocampal lesions and their relationship to epilepsy we studied autopsy specimens from the hippocampi of a series of patients with the infantile (CLN1), classic late infantile (CLN2), Finnish variant late infantile (CLN5), and juvenile (CLN3) neuronal ceroid-lipofuscinosis as well as Northern epilepsy (CLN8), using a battery of histological and immunocytochemical staining methods. Despite striking differences in the overall degree of neocortical neuronal storage and loss, these genetically heterogeneous forms of neuronal ceroid lipofuscinosis showed a common lesional pattern in the hippocampi: a relative sparing of the CA1 sector and severe involvement of the neighbouring CA2 sector, with intermediate degrees of involvement of the CA3 and CA4 sectors. These findings distinguish the hippocampal pathology associated with the neuronal ceroid lipofuscinoses from classical 'mesial temporal sclerosis' and show that the selective lesional pattern in the neuronal ceroid lipofuscinoses is not a secondary anoxic-ischaemic phenomenon. It is rather a consequence of the primary metabolic defects and may be directly involved in the causation of the epileptic discharges. Show less
no PDF DOI: 10.1053/eipn.2000.0464
CLN3
V J Muller, B C Paton, M J Fietz · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
The neuronal ceroid lipofuscinoses (NCLs) are a family of related genetic disorders that together are believed to affect one child in every 12,500 births in the USA. Our laboratory has developed a dia Show more
The neuronal ceroid lipofuscinoses (NCLs) are a family of related genetic disorders that together are believed to affect one child in every 12,500 births in the USA. Our laboratory has developed a diagnostic service for classical late infantile neuronal ceroid lipofuscinosis (LINCL) by assay of tripeptidyl-peptidase I (TPP-I) activity using the fluorogenic peptide substrate Ala-Ala-Phe aminomethylcoumarin, followed by a screen for three mutations in the CLN2 gene. In addition, we have also begun to offer a limited diagnostic service for the juvenile (JNCL) and infantile (INCL) forms of the disease on the basis of mutation analysis of the CLN3 and CLN1 genes, respectively. Retrospective analysis of Australasian patients with a clinical suspicion of NCL has revealed that six are affected by LINCL, six by JNCL and, to date, two by INCL. Mutation analysis of our LINCL patients has shown that the three screened mutations, namely, the nonsense mutation R208X and the splice mutations IVS5-1 G > C and IVS5-1 G > A, constitute 83% of alleles. Show less
no PDF DOI: 10.1053/eipn.2000.0462
CLN3
L Lauronen, P Santavuori, A Hirvasniemi +3 more · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to Show more
Northern epilepsy syndrome (NES, EPMR, progressive epilepsy with mental retardation, CLN8), an inherited childhood-onset epilepsy with mental retardation, has been recently characterized to belong to the family of neuronal ceroid lipofuscinoses (NCLs). In this study, four patients (ages 26-44 years) with NES and eight healthy controls underwent magnetic resonance imaging (MRI) and electrophysiological evaluation with somatosensory evoked magnetic field (SEF) studies. The findings in NES were compared with the known findings in juvenile NCL (JNCL, CLN3) and Finnish variant late infantile NCL (vLINCLFIN, CLN5) that manifest around the same age as NES. Also postmortem MRI was performed on one brain. On the MRIs, slight to moderate cerebellar atrophy was seen in all patients, whereas only two patients had slightly enlarged cerebral sulci. None of the MRIs demonstrated signal intensity abnormalities that are commonly seen in JNCL and vLINCLFIN and are considered to reflect the Wallerian degeneration after neuronal death. Generally SEFs in NES were within normal limits, indicating that the disease had not impaired the function of the neurons on the somatosensory pathway. In conclusion, MRI imaging and SEF findings suggest that the cerebral neuronal death and dysfunction in NES are minimal compared with JNCL and vLINCLFIN. Show less
no PDF DOI: 10.1053/ejpn.2000.0456
CLN3
P Santavuori, S L Vanhanen, T Autti · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
Early diagnosis is mandatory for avoiding further cases in families with hereditary metabolic brain disorders. This review lists the most important clinical symptoms and neuroradiological findings at Show more
Early diagnosis is mandatory for avoiding further cases in families with hereditary metabolic brain disorders. This review lists the most important clinical symptoms and neuroradiological findings at the early stage of the seven most common childhood neuronal ceroid lipofuscinoses (NCL) types. In the infantile type the typical magnetic resonance imaging (MRI) findings can be seen even before the clinical signs. In the classic late infantile type (CLN2), MRI is less informative but in this and in the variant late infantile type CLN6 the characteristic neurophysiological findings are present at an early stage, although not in the Finnish variant CLN5. In the latter, the clinical diagnosis depends on ophthalmological and MRI findings. The combination of ophthalmological deficits and vacuolated lymphocytes is highly characteristic of the juvenile type (CLN3). A new NCL type, Northern epilepsy (CLN8), is also briefly reviewed. Show less
no PDF DOI: 10.1053/ejpn.2000.0454
CLN3
A M Das, R von Harlem, M Feist +2 more · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
The pathogenesis of neurodegeneration in neuronal ceroid lipofuscinosis (NCL) is still not clear despite progress in mutation analysis of these diseases. We have recently observed anomalies at the lev Show more
The pathogenesis of neurodegeneration in neuronal ceroid lipofuscinosis (NCL) is still not clear despite progress in mutation analysis of these diseases. We have recently observed anomalies at the level of the mitochondrial ATPsynthase (complex V of the respiratory chain) in fibroblasts from children with CLN1, CLN2, CLN3 and in an ovine model (OCL6). The measurements were carried out in vitro. If these alterations were of relevance in vivo as well, contents of high-energy phosphate compounds should be reduced. In the present study, we measured levels of creatine phosphate (CP), ATP, ADP and AMP in fibroblasts from children with CLN1, CLN2, CLN3 and in OCL6. ATP was reduced to about 50% of normal in CLN1, CLN2 and CLN3, ADP was about 30% of normal in these cells, and CP was 50% of normal in CLN1 and CLN2 but remained normal in CLN3. In fibroblasts of NCL-sheep, however, CP and ADP were increased to 690% and 220% of normal, respectively, while ATP remained normal. If the anomalies found in cellular energy metabolism in fibroblasts were expressed in neurons from NCL patients and NCL sheep 'slow-onset excitotoxicity' could occur leading to cellular dysfunction and eventually to cell death. Show less
no PDF DOI: 10.1053/ejpn.2000.0451
CLN3
K J Barwell, M F Broom · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
The gene involved in the classical juvenile form of Batten disease, CLN3 has been identified as being highly homologous to the Saccharomyces cerevisiae YHC3 gene. To provide a simple model for the bio Show more
The gene involved in the classical juvenile form of Batten disease, CLN3 has been identified as being highly homologous to the Saccharomyces cerevisiae YHC3 gene. To provide a simple model for the biochemical events underlying this disease, several disruptions have been made in YHC3 in three different S. cerevisiae strains. No obvious growth differences were observed, and neither was the previously reported phenotypic difference between wild-type and yeast disrupted in YHC3. Show less
no PDF DOI: 10.1053/ejpn.2000.044
CLN3
G de Voer, G Jansen, G J van Ommen +2 more · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
Neuronal ceroid lipofuscinoses (NCLs) are the most common hereditary neurodegenerative disorders of childhood. The first symptom of this heterogeneous group of devastating lysosomal storage diseases i Show more
Neuronal ceroid lipofuscinoses (NCLs) are the most common hereditary neurodegenerative disorders of childhood. The first symptom of this heterogeneous group of devastating lysosomal storage diseases is progressive visual failure. The different forms of NCL can be distinguished by age of onset, clinical features and the characteristics of the accumulated materials. The juvenile form, Batten-Spielmeyer-Vogt disease which is caused by mutations in the CLN3 gene, is the most frequent form of the disease in which loss of vision becomes apparent around the age of 5-8 years. The gene was found to encode a novel integral membrane protein localizing to the lysosomes, confirming that the primary defect in NCL is in lysosomal function. The CLN3 protein function is still unknown, and is examined in several model organisms. We are studying the nematode Caenorhabditis elegans, and have identified three CLN3 homologues. In order to investigate the role of the CLN3 protein in C. elegans, Cecln-3 deletion mutants are being isolated from an ethyl methanesulphonate (EMS)-induced deletion mutant library. Examination of these mutants may provide us with information that will help in dissecting the processes in which the CLN3 protein is involved. In this library two mutated C. elegans Cln-3 loci have been identified, of which one mutant, NL748, was isolated. This mutant contains a deletion of the whole gene. The deletion mutant was characterized with regard to life expectancy, and showed no significant differences when compared with wild-type. Show less
no PDF DOI: 10.1053/ejpn.2000.0446
CLN3
M L Katz, G S Johnson · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
The childhood neuronal ceroid-lipofuscinoses (NCLs) are autosomal-recessively inherited neurodegenerative disorders that result in severe cognitive decline and premature death. The genetic bases for a Show more
The childhood neuronal ceroid-lipofuscinoses (NCLs) are autosomal-recessively inherited neurodegenerative disorders that result in severe cognitive decline and premature death. The genetic bases for a number of different forms of NCL, including those designated CLN2 and CLN3, have now been determined. However, the mechanisms by which the gene defects cause the disease pathology are not known and no effective treatments for these disorders have been developed. To provide tools for studying the mechanisms underlying the disease pathologies and for screening potential therapeutic interventions, work is under way to develop mouse models for the CLN2 and CLN3 disorders. Targeted gene replacement was used to generate mice in which the murine orthologue of the CLN3 gene has been knocked out. Mice that are homozygous for the Cln3 knockout allele develop a number of pathological features similar to those that occur in the human disorder. Among these are accumulation of autofluorescent lysosomal storage bodies, behavioural abnormalities, retinal degeneration, and premature death. On a mixed strain genetic background, the appearance of these symptoms was quite variable, suggesting that other genes can modify the effects of CLN3 mutations. Work to develop a similar mouse gene knockout model for the CLN2 disorder is well under way. Chimaeric mice have been developed with cells that carry an induced mutation in the mouse orthologue of the CLN2 gene that would prevent synthesis of a functional CLN2 protein in mice that are homozygous for the mutation. Mice will be developed that are homozygous for this mutation, and these animals will be evaluated for the development of pathologies similar to those that occur in the human disorder. Show less
no PDF DOI: 10.1053/ejpn.2000.0445
CLN3
N D Greene, M F Lythgoe, D L Thomas +3 more · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
Batten disease, the juvenile-onset form of neuronal ceroid lipofuscinosis (NCL), is a progressive neurodegenerative disorder of childhood with an age of onset of 5-10 years of age. JNCL is caused by m Show more
Batten disease, the juvenile-onset form of neuronal ceroid lipofuscinosis (NCL), is a progressive neurodegenerative disorder of childhood with an age of onset of 5-10 years of age. JNCL is caused by mutations in the CLN3 gene which encodes a membrane protein of unknown function. Magnetic resonance imaging of the brain of juvenile NCL patients has revealed changes in signal intensity and tissue atrophy, predominantly in the cortex and cerebellum. A mouse model for Batten disease was created by targeted disruption of the murine Cln3 gene in order to further understanding of the pathophysiology of Batten disease and to evaluate potential therapeutic approaches. Several features of the disease are displayed by Cln3 mice including accumulation of characteristic storage material in neurons. The aim of this work was to investigate neurodegeneration in the Cln3 mouse model using high resolution magnetic resonance imaging to measure signal intensity ratios in selected regions of interest. Global changes were observed in the brains of 12-month-old mutant mice that mirror those seen in juvenile NCL patients. There is a decrease in signal intensity ratio in grey matter regions including cortex, hippocampus and cerebellum, tissues where neuronal storage accumulation and cell loss have been seen in the mouse model. The alterations seen in Cln3 mutant mice support the validity of further imaging studies and suggest that this method will have application in assessment of therapeutic approaches in the study of mutant mouse models of NCL including the Cln3 mouse. Show less
no PDF DOI: 10.1053/ejpn.2000.0444
CLN3
A V Delgado-Escueta, S Ganesh, K Yamakawa · 2001 · American journal of medical genetics · Wiley · added 2026-04-24
The genetic progressive myoclonus epilepsies (PMEs) are clinically characterized by the triad of stimulus sensitive myoclonus (segmental lightning like muscular jerks), epilepsy (grand mal and absence Show more
The genetic progressive myoclonus epilepsies (PMEs) are clinically characterized by the triad of stimulus sensitive myoclonus (segmental lightning like muscular jerks), epilepsy (grand mal and absences) and progressive neurologic deterioration (dementia, ataxia, and various neurologic signs depending on the cause). Etiologically heterogenous, PMEs are rare and mostly autosomal recessive disorders, with the exception of autosomal dominant dentatorubral-pallidoluysian atrophy and mitochondrial encephalomyopathy with ragged red fibers (MERRF). In the last five years, specific mutations have been defined in Lafora disease (gene for laforin or dual specificity phosphatase in 6q24), Unverricht-Lundborg disease (cystatin B in 21q22.3), Jansky-Bielschowsky ceroid lipofuscinoses (CLN2 gene for tripeptidyl peptidase 1 in 11q15), Finnish variant of late infantile ceroid lipofuscinoses (CLN5 gene in 13q21-32 encodes 407 amino acids with two transmembrane helices of unknown function), juvenile ceroid lipofuscinoses or Batten disease (CLN3 gene in 16p encodes 438 amino acid protein of unknown function), a subtype of Batten disease and infantile ceroid lipofuscinoses of the Haltia-Santavuori type (both are caused by mutations in palmitoyl-protein thiosterase gene at 1p32), dentadorubropallidoluysian atrophy (CAG repeats in a gene in 12p13.31) and the mitochondrial syndrome MERRF (tRNA Lys mutation in mitochondrial DNA). In this review, we cover mainly these rapid advances. Show less
no PDF DOI: 10.1002/ajmg.1575
CLN3
K E Wisniewski, N Zhong, M Philippart · 2001 · Neurology · added 2026-04-24
The neuronal ceroid lipofuscinoses (NCL) are a large group of autosomal recessive lysosomal storage disorders with both enzymatic deficiency and structural protein dysfunction. Previously, diagnosis o Show more
The neuronal ceroid lipofuscinoses (NCL) are a large group of autosomal recessive lysosomal storage disorders with both enzymatic deficiency and structural protein dysfunction. Previously, diagnosis of NCL was based on age at onset and clinicopathologic (C-P) findings, classified as 1) infantile (INCL), 2) late infantile (LINCL), 3) juvenile (JNCL), and 4) adult (ANCL). Most patients with NCL have progressive ocular and cerebral dysfunction, including cognitive/motor dysfunction and uncontrolled seizures. After reviewing 319 patients with NCL, the authors found that 64 (20%) did not fit into this classification of NCL. With research progress, four additional forms have been recognized: 5) Finnish, 6) Gypsy/Indian, and 7) Turkish variants of LINCL and 8) northern epilepsy, also known as progressive epilepsy with mental retardation. These eight NCL forms resulted from 100 different mutations on genes CLN1to CLN8 causing different phenotypes (http://www.ucl.ac.uk/ncl). The genes CLN1 and CLN2 encode lysosomal palmitoyl protein thioesterase and tripeptidyl peptidase 1. The function of CLN3, CLN5, and CLN8 gene-encoded products is unknown, although their predicted amino acid sequences suggest they have a transmembrane topology. The diagnosis of NCL is based on C-P findings, enzymatic assay, and molecular genetic testing. Before biochemical and genetic tests are conducted, ultrastructural studies (i.e., blood [buffy coat] or punch biopsies [skin, conjunctiva]) must be performed to confirm the presence and nature of lysosomal storage material (fingerprint or curvilinear profiles or granular osmiophilic deposits). The recognition of variable onset from infancy to middle age supersedes the traditional emphasis on age-related NCL forms. Show less
no PDF DOI: 10.1212/wnl.57.4.576
CLN3
M E Miller, F R Cross · 2001 · Molecular and cellular biology · added 2026-04-24
Different G(1) cyclins confer functional specificity to the cyclin-dependent kinase (Cdk) Cdc28p in budding yeast. The Cln3p G(1) cyclin is localized primarily to the nucleus, while Cln2p is localized Show more
Different G(1) cyclins confer functional specificity to the cyclin-dependent kinase (Cdk) Cdc28p in budding yeast. The Cln3p G(1) cyclin is localized primarily to the nucleus, while Cln2p is localized primarily to the cytoplasm. Both binding to Cdc28p and Cdc28p-dependent phosphorylation in the C-terminal region of Cln2p are independently required for efficient nuclear depletion of Cln2p, suggesting that this process may be physiologically regulated. The accumulation of hypophosphorylated Cln2 in the nucleus is an energy-dependent process, but may not involve the RAN GTPase. Phosphorylation of Cln2p is inefficient in small newborn cells obtained by elutriation, and this lowered phosphorylation correlates with reduced Cln2p nuclear depletion in newborn cells. Thus, Cln2p may have a brief period of nuclear residence early in the cell cycle. In contrast, the nuclear localization pattern of Cln3p is not influenced by Cdk activity. Cln3p localization requires a bipartite nuclear localization signal (NLS) located at the C terminus of the protein. This sequence is required for nuclear localization of Cln3p and is sufficient to confer nuclear localization to green fluorescent protein in a RAN-dependent manner. Mislocalized Cln3p, lacking the NLS, is much less active in genetic assays specific for Cln3p, but more active in assays normally specific for Cln2p, consistent with the idea that Cln3p localization explains a significant part of Clnp functional specificity. Show less
no PDF DOI: 10.1128/MCB.21.18.6292-6311.2001
CLN3
C Anthony, Q Zong, A De Benedetti · 2001 · The Journal of biological chemistry · American Society for Biochemistry and Molecular Biology · added 2026-04-24
The association of G(1) cyclins and Cdc28/cyclin-dependent protein kinase catalyzes the cell cycle entry (Start) in budding yeast. Activation of Start is presumed to be triggered by a post-transcripti Show more
The association of G(1) cyclins and Cdc28/cyclin-dependent protein kinase catalyzes the cell cycle entry (Start) in budding yeast. Activation of Start is presumed to be triggered by a post-transcriptional increase in Cln3 during early G(1). Cells arrested by mating pheromone show a loss of cyclin-dependent protein kinase activity caused by transcriptional shutoff of cyclins and/or inhibition by Far1. We report that overexpression of eIF4E (Cdc33), a rate-limiting translation initiation factor, causes an increase in CLN3 mRNA translation, which results in increased expression of CLN2 and in slow growth and decreased alpha-factor response. This phenotype was abrogated in a Deltacln3 or Deltacln2 background. We isolated the transcription factor MBP1 as a multicopy suppressor of the growth and alpha-factor response defects. Furthermore, elevated MBP1, a transcriptional regulator of cyclins, altered the transcriptional start site in CLN3 mRNA, shifting it 45 nucleotides upstream of the normal. This lengthened 5'-untranslated region likely reduces translation efficiency and down-regulates CLN3 protein synthesis, thereby correcting for the excess translation promoted by elevated Cdc33. In addition, the CLN2 mRNA level returned to normal. We propose that regulation of translation initiation by Cdc33 plays a pivotal role in the activation of Start and cell cycle progression in budding yeast. Show less
no PDF DOI: 10.1074/jbc.M101564200
CLN3
H Martin-Yken, A Dagkessamanskaia, P De Groot +3 more · 2001 · Yeast (Chichester, England) · Wiley · added 2026-04-24
The Saccharomyces cerevisiae cwh43-2 mutant, originally isolated for its Calcofluor white hypersensitivity, displays several cell wall defects similar to mutants in the PKC1-MPK1 pathway, including a Show more
The Saccharomyces cerevisiae cwh43-2 mutant, originally isolated for its Calcofluor white hypersensitivity, displays several cell wall defects similar to mutants in the PKC1-MPK1 pathway, including a growth defect and increased release of beta-1,6-glucan and beta-glucosylated proteins into the growth medium at increased temperatures. The cloning of CWH43 showed that it corresponds to YCR017c and encodes a protein with 14-16 transmembrane segments containing several putative phosphorylation and glycosylation sites. The N-terminal part of the amino acid sequence of Cwh43p shows 40% similarity with the mammalian FRAG1, a membrane protein that activates the fibroblast growth factor receptor of rat osteosarcoma (FGFR2-ROS) and with protein sequences of four uncharacterized ORFs from Caenorhabditis elegans and one from Drosophila melanogaster. The C-terminus of Cwh43p shows low similarities with a xylose permease of Bacillus megaterium and with putative sugar transporter from D. melanogaster, and has 52% similarity with a protein sequence from a Schizosaccharomyces pombe cDNA. A Cwh43-GFP fusion protein suggested a plasma membrane localization, although localization to the internal structure of the cells could not be excluded, and it concentrates to the bud tip of small budded cells and to the neck of dividing cells. Deletion of CWH43 resulted in cell wall defects less pronounced than those of the cwh43-2 mutant. This allele-specific phenotype appears to be due to a G-R substitution at position 57 in a highly conserved region of the protein. Genetic analysis places CWH43 upstream of the BCK2 branch of the PKC1 signalling pathway, since cwh43 mutations were synthetic lethal with pkc1 deletion, whereas the cwh43 defects could be rescued by overexpression of BCK2 and not by high-copy-number expression of genes encoding downstream proteins of the PKC1 pathway However, unlike BCK2, whose disruption in a cln3 mutant resulted in growth arrest in G(1), no growth defect was observed in a double cwh43 cln3 mutants. Taken together, it is proposed that CWH43 encodes a protein with putative sensor and transporter domains acting in parallel to the main PKC1-dependent cell wall integrity pathway, and that this gene has evolved into two distinct genes in higher eukaryotes. Show less
no PDF DOI: 10.1002/yea.731
CLN3
E W Trotter, L Berenfeld, S A Krause +2 more · 2001 · Proceedings of the National Academy of Sciences of the United States of America · National Academy of Sciences · added 2026-04-24
Accumulation of misfolded proteins in the cell at high temperature may cause entry into a nonproliferating, heat-shocked state. The imino acid analog azetidine 2-carboxylic acid (AZC) is incorporated Show more
Accumulation of misfolded proteins in the cell at high temperature may cause entry into a nonproliferating, heat-shocked state. The imino acid analog azetidine 2-carboxylic acid (AZC) is incorporated into cellular protein competitively with proline and can misfold proteins into which it is incorporated. AZC addition to budding yeast cells at concentrations sufficient to inhibit proliferation selectively activates heat shock factor (HSF). We find that AZC treatment fails to cause accumulation of glycogen and trehalose (Msn2/4-dependent processes) or to induce thermotolerance (a protein kinase C-dependent process). However, AZC-arrested cells can accumulate glycogen and trehalose and can acquire thermotolerance in response to a subsequent heat shock. We find that AZC treatment arrests cells in a viable state and that this arrest is reversible. We find that cells at high temperature or cells deficient in the ubiquitin-conjugating enzymes Ubc4 and Ubc5 are hypersensitive to AZC-induced proliferation arrest. We find that AZC treatment mimics temperature up-shift in arresting cells in G1 and represses expression of CLN1 and CLN2. Mutants with reduced G1 cyclin-Cdc28 activity are hypersensitive to AZC-induced proliferation arrest. Expression of the hyperstable Cln3-2 protein prevents G1 arrest upon AZC treatment and temperature up-shift. Finally, we find that the EXA3-1 mutation, encoding a defective HSF, prevents efficient G1 arrest in response to both temperature up-shift and AZC treatment. We conclude that nontoxic levels of misfolded proteins (induced by AZC treatment or by high temperature) selectively activate HSF, which is required for subsequent G1 arrest. Show less
no PDF DOI: 10.1073/pnas.121172998
CLN3
V L MacKay, B Mai, L Waters +1 more · 2001 · Molecular and cellular biology · added 2026-04-24
The Cln3-Cdc28 kinase is required to activate the Swi4-Swi6 transcription complex which induces CLN1 and CLN2 transcription in late G(1) and drives the transition to S. Cln3 and Swi4 are both rate lim Show more
The Cln3-Cdc28 kinase is required to activate the Swi4-Swi6 transcription complex which induces CLN1 and CLN2 transcription in late G(1) and drives the transition to S. Cln3 and Swi4 are both rate limiting for G(1) progression, and they are coordinately transcribed to peak at the M/G(1) boundary. Early cell cycle box (ECB) elements, which confer M/G(1)-specific transcription, have been found in both promoters, and elimination of all ECB elements from the CLN3 promoter causes both a loss of periodicity and Cln3-deficient phenotypes, which include an extended G(1) interval and increased cell volume. Mutants lacking the ECB elements in both the CLN3 and SWI4 promoters have low and deregulated levels of CLN transcripts, and the G(1)-to-S transition for these mutants is delayed and highly variable. These observations support the view that the coordinated rise of Cln3 and Swi4 levels mediated by ECB-dependent transcription controls the timing of the G(1)-to-S phase transition. Show less
no PDF DOI: 10.1128/MCB.21.13.4140-4148.2001
CLN3
M A Junaid, R K Pullarkat · 2001 · Advances in genetics · Elsevier · added 2026-04-24
This chapter summarizes the recent advances that have been made with respect to biochemical characterization of the neurodegenerative diseases collectively known as neuronal ceroid lipofuscinoses (NCL Show more
This chapter summarizes the recent advances that have been made with respect to biochemical characterization of the neurodegenerative diseases collectively known as neuronal ceroid lipofuscinoses (NCL) or Batten disease. Genomic and proteomic approaches have presently identified eight different forms of NCL (namely, CLN1 through CLN8) based on mutations in specific genes. CLN1 and CLN2 are caused by mutations in genes that encodes lysosomal enzymes,palmitoyl protein thioesterase and pepstatin-insensitive proteinase, respectively. The protein involved in the etiology of CLN3 is a highly hydrophobic, presumably transmembrane protein. NCL are considered as lysosomal storage diseases because of the accumulation of autofluorescent inclusion bodies. The composition of inclusion bodies varies in different forms of the NCL. The major storage component in CLN2 is the subunit c of mitochondrial ATP synthase complex and its accumulation is the direct result of lack of CLN2p in this disease. Mannose-6-phosphorylated glycoproteins accumulate in CLN3 and most likely their accumulation is the result of an intrinsic activity of the CLN3 protein. Significant levels of oligosaccharyl diphosphodolichol also accumulate in CLN3 and CLN2, whereas lysosomal sphingolipid activator proteins (saposins A and D) constitute major component of the storage material in CLN 1. The issue of selective loss of neuronal and retinal cells in NCL still remains to be addressed. Identification of natural substrates for the various enzymes involved in NCL may help in the characterization of the cytotoxic factor(s) and also in designing rationale therapeutic interventions for these group of devastating diseases. Show less
no PDF DOI: 10.1016/s0065-2660(01)45005-x
CLN3
G Bellí, E Garí, M Aldea +1 more · 2001 · Molecular microbiology · added 2026-04-24
Moderate hyperosmotic stress on Saccharomyces cerevisiae cells produces a temporary delay at the G1 stage of the cell cycle. This is accompanied by transitory downregulation of CLN1, CLN2 and CLB5 tra Show more
Moderate hyperosmotic stress on Saccharomyces cerevisiae cells produces a temporary delay at the G1 stage of the cell cycle. This is accompanied by transitory downregulation of CLN1, CLN2 and CLB5 transcript levels, although not of CLN3, which codes for the most upstream activator of the G1/S transition. Osmotic shock to cells synchronized in early G1, when Cln3 is the only cyclin present, causes a delay in cell cycle resumption. This points to Cln3 as being a key cell cycle target for osmotic stress. We have observed that osmotic shock causes downregulation of the kinase activity of Cln3-Cdc28 complexes. This is concomitant with a temporary accumulation of Cln3 protein as a result of increased stability. The effects of the osmotic stress in G1 are not suppressed in CLN3-1 cells with increased kinase activity, as the Cln3-Cdc28 activity in this mutant is still affected by the shock. Although Hog1 is not required for the observed cell cycle arrest in hyperosmotic conditions, it is necessary to resume the cell cycle at KCl concentrations higher than 0.4 M. Show less
no PDF DOI: 10.1046/j.1365-2958.2001.02297.x
CLN3
E Kida, A A Golabek, K E Wisniewski · 2001 · Advances in genetics · Elsevier · added 2026-04-24
Lysosomal accumulation of autofluorescent, ceroid lipopigment material in various tissues and organs is a common feature of the neuronal ceroid lipofuscinoses (NCLs). However, recent clinicopathologic Show more
Lysosomal accumulation of autofluorescent, ceroid lipopigment material in various tissues and organs is a common feature of the neuronal ceroid lipofuscinoses (NCLs). However, recent clinicopathologic and genetic studies have evidenced that NCLs encompass a group of highly heterogeneous disorders. In five of the eight NCL variants distinguished at present, genes associated with the disease process have been isolated and characterized (CLN1, CLN2, CLN3, CLN5, CLN8). Only products of two of these genes, CLN 1 and CLN2, have structural and functional properties of lysosomal enzymes. Nevertheless, according to the nature of the material accumulated in the lysosomes, NCLs in humans as well as natural animal models of these disorders can be divided into two major groups: those characterized by the prominent storage of saposins A and D, and those showing the predominance of subunit c of mitochondrial ATP synthase accumulation. Thus, taking into account the chemical character of the major component of the storage material, NCLs can be classified currently as proteinoses. Of importance, although lysosomal storage material accumulates in NCL subjects in various organs, only brain tissue shows severe dysfunction and cell death, another common feature of the NCL disease process. However, the relation between the genetic defects associated with the NCL forms, the accumulation of storage material, and tissue damage is still unknown. This chapter introduces the reader to the complex pathogenesis of NCLs and summarizes our current knowledge of the potential consequences of the genetic defects of NCL-associated proteins on the biology of the cell. Show less
no PDF DOI: 10.1016/s0065-2660(01)45003-6
CLN3
D A Pearce · 2001 · Advances in genetics · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/s0065-2660(01)45012-7
CLN3
M L Katz, H Shibuya, G S Johnson · 2001 · Advances in genetics · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/s0065-2660(01)45011-5
CLN3
N Zhong · 2001 · Advances in genetics · Elsevier · added 2026-04-24
Eight different NCL forms have been recognized to be encoded by genes CLN1-8. CLN1,2,3,5,and 8 have been cloned, and at least 85 mutations have been detected. Molecular technology can now be applied t Show more
Eight different NCL forms have been recognized to be encoded by genes CLN1-8. CLN1,2,3,5,and 8 have been cloned, and at least 85 mutations have been detected. Molecular technology can now be applied to genetic testing for NCLs; testing is now available in clinic diagnostic and research laboratories for CLN genes that have been cloned. Molecular genetic testing makes it possible not only to confirm clinical and pathological diagnoses but also to offer pre-symptom diagnosis and carrier screening for NCL families. In addition, DNA-based mutation analysis may predict prenatal outcome more accurately for pregnant women in NCL families. Show less
no PDF DOI: 10.1016/s0065-2660(01)45008-5
CLN3
T J Lerner · 2001 · Advances in genetics · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/s0065-2660(01)45006-1
CLN3
K E Wisniewski, E Kida, A A Golabek +3 more · 2001 · Advances in genetics · Elsevier · added 2026-04-24
The neuronal ceroid lipofuscinoses (NCLs) are neurodegenerative disorders characterized by accumulation of ceroid lipopigment in lysosomes in various tissues and organs. The childhood forms of the NCL Show more
The neuronal ceroid lipofuscinoses (NCLs) are neurodegenerative disorders characterized by accumulation of ceroid lipopigment in lysosomes in various tissues and organs. The childhood forms of the NCLs represent the most common neurogenetic disorders of childhood and are inherited in an autosomal-recessive mode. The adult form of NCL is rare and shows either an autosomal-recessive or autosomal dominant mode of inheritance. Currently, five genes associated with various childhood forms of NCLs, designated CLN1, CLN2, CLN3, CLN5, and CLN8, have been isolated and characterized. Two of these genes, CLN1 and CLN2, encode lysosomal enzymes: palmitoyl protein thioesterase 1 (PPT1) and tripetidyl peptidase 1 (TPP1), respectively. CLN3, CLN5, and CLN8 encode proteins of predicted transmembrane topology, whose function has not been characterized yet. Two other genes, CLN6 and CLN7, have been assigned recently to small chromosomal regions. Gene(s) associated with the adult form of NCLs (CLN4) are at present unknown. This study summarizes the current classification and new diagnostic criteria of NCLs based on clinicopathological, biochemical, and molecular genetic data. Material includes 159 probands with NCL (37 CLNI, 72 classical CLN2, 10 variant LINCL, and 40 CLN3) collected at the New York State Institute for Basic Research in Developmental Disabilities (IBR) as well as a comprehensive review of the literature. The results of our study indicate that although only biochemical and molecular genetic studies allow for definitive diagnosis, ultrastructural studies of the biopsy material are still very useful. Thus, although treatments for NCLs are not available at present, the diagnosis has become better defined. Show less
no PDF DOI: 10.1016/s0065-2660(01)45002-4
CLN3
R S Nash, T Volpe, B Futcher · 2001 · Genetics · Oxford University Press · added 2026-04-24
WHI3 is a gene affecting size control and cell cycle in the yeast Saccharomyces cerevisiae. The whi3 mutant has small cells, while extra doses of WHI3 produce large cells, and a large excess of WHI3 p Show more
WHI3 is a gene affecting size control and cell cycle in the yeast Saccharomyces cerevisiae. The whi3 mutant has small cells, while extra doses of WHI3 produce large cells, and a large excess of WHI3 produces a lethal arrest in G1 phase. WHI3 seems to be a dose-dependent inhibitor of Start. Whi3 and its partially redundant homolog Whi4 have an RNA-binding domain, and mutagenesis experiments indicate that this RNA-binding domain is essential for Whi3 function. CLN3-1 whi3 cells are extremely small, nearly sterile, and largely nonresponsive to mating factor. Fertility is restored by deletion of CLN2, suggesting that whi3 cells may have abnormally high levels of CLN2 function. Show less
no PDF DOI: 10.1093/genetics/157.4.1469
CLN3
W Zhou, G M Edelman, V P Mauro · 2001 · Proceedings of the National Academy of Sciences of the United States of America · National Academy of Sciences · added 2026-04-24
In higher eukaryotes, translation of some mRNAs occurs by internal initiation. It is not known, however, whether this mechanism is used to initiate the translation of any yeast mRNAs. In this report, Show more
In higher eukaryotes, translation of some mRNAs occurs by internal initiation. It is not known, however, whether this mechanism is used to initiate the translation of any yeast mRNAs. In this report, we identify naturally occurring nucleotide sequences that function as internal ribosome entry sites (IRESes) within the 5' leader sequences of Saccharomyces cerevisiae YAP1 and p150 mRNAs. When tested in the 5' untranslated regions of monocistronic reporter genes, both leader sequences enhanced translation efficiency in vegetatively growing yeast cells. Moreover, when tested in the intercistronic region of dicistronic mRNAs, both sequences were shown to contain IRESes that functioned in living cells. The activity of the p150 leader was much greater than that of the YAP1 leader. The second cistron was not expressed in control dicistronic constructs that lacked these sequences or contained the 5' leader sequence of the CLN3 mRNA in the intercistronic region. Further analyses of the p150 IRES revealed that it contained several nonoverlapping segments that were able independently to mediate internal initiation. These results suggested a modular composition for the p150 IRES that resembled the composition of IRESes contained within some cellular mRNAs of higher eukaryotes. Both YAP1 and p150 leaders contain several complementary sequence matches to yeast 18S rRNA. The findings are discussed in terms of our understanding of internal initiation in higher eukaryotes. Show less
no PDF DOI: 10.1073/pnas.98.4.1531
CLN3
G M Jenkins, Y A Hannun · 2001 · The Journal of biological chemistry · American Society for Biochemistry and Molecular Biology · added 2026-04-24
The recent findings of sphingolipids as potential mediators of yeast heat stress responses led us to investigate their possible role in the heat-induced cell cycle arrest and subsequent recovery. The Show more
The recent findings of sphingolipids as potential mediators of yeast heat stress responses led us to investigate their possible role in the heat-induced cell cycle arrest and subsequent recovery. The sphingolipid-deficient yeast strain 7R4 was found to lack the cell cycle arrest seen in the isogenic wild type. Furthermore, strain lcb1-100, which harbors a temperature-sensitive serine palmitoyltransferase, lacked increased de novo generated sphingoid bases upon heat stress. Importantly, this strain was found to lack the transient heat-induced G0/G1 arrest. These results indicate a role for sphingolipids and specifically those generated in the de novo pathway in the cell cycle arrest response to heat. To determine the bioactive sphingolipid regulating this response, an analysis of key mutants in the sphingolipid biosynthetic and degradation pathways was performed. Strains deleted in sphingoid base kinases, sphingoid phosphate phosphatase, lyase, or dihydrosphingosine hydroxylase were found to display the cell cycle arrest. Also, the knockout of a fatty acyl elongation enzyme, which severely attenuates ceramide production, displayed the arrest. These experiments suggested that the active species for cell cycle arrest were the sphingoid bases. In further support of these findings, exogenous phytosphingosine (10 microM) was found to induce transient arrest. Stearylamine did not induce an arrest, demonstrating chemical specificity, and L-erythro- was not as potent as D-erythro-dihydrosphingosine showing stereospecificity. To investigate a possible arrest mechanism, we studied the hyperstable Cln3 (Cln3-1) strain LDW6A that has been previously shown to be resistant to heat stress-induced cell cycle arrest. The strain containing Cln3-1 was found to be resistant to cell cycle arrest induced by exogenous phytosphingosine, indicating that Cln3 acts downstream of the sphingoid bases in this response. Interestingly, cell cycle recovery from the transient arrest was found to be dependent upon the sphingoid base kinases (LCB4, LCB5). Overall, this combination of genetic and pharmacologic results demonstrates a role for de novo sphingoid base biosynthesis by serine palmitoyltransferase in the transient G0/G1 arrest mediated through Cln3 via a novel mechanism. Show less
no PDF DOI: 10.1074/jbc.M007425200
CLN3
W A Mitchell, M Porter, P Kuwabara +1 more · 2001 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · added 2026-04-24
The genome of Caenorhabditis elegans is predicted to carry three genes similar to CLN3, the gene underlying juvenile neuronal ceroid lipofuscinosis. All three genes are transcribed and the genomic str Show more
The genome of Caenorhabditis elegans is predicted to carry three genes similar to CLN3, the gene underlying juvenile neuronal ceroid lipofuscinosis. All three genes are transcribed and the genomic structure has been determined. The number and position of exons for two of the genes differ from that predicted from the genomic sequence, but no discrepancies with the genomic nucleotide sequence were found. Gene F07B10.1 (cln-3.1) is predicted to have 7 exons and to encode a protein of 424 amino acids. Gene C01G8.2 (cln-3.2) has 9 exons and encodes a protein of 435 amino acids. Gene ZC190.1 (cln-3.3) is predicted to have 9 exons and to encode a protein of 416 amino acids. Show less
no PDF DOI: 10.1053/ejpn.2000.0447
CLN3
S Chattopadhyay, D A Pearce · 2000 · Molecular genetics and metabolism · added 2026-04-24
The neuronal ceroid lipofuscinoses (NCLs) are the most common neurodegenerative disorders of childhood. We have examined mRNA levels of the CLN1, CLN2, and CLN3 genes, which are associated with the in Show more
The neuronal ceroid lipofuscinoses (NCLs) are the most common neurodegenerative disorders of childhood. We have examined mRNA levels of the CLN1, CLN2, and CLN3 genes, which are associated with the infantile, late infantile, and juvenile forms of NCL in 64 different human tissues, and have grouped the results into gastrointestinal tract, central nervous system, glandular/secretory, muscle, and carcinoma tissue types. mRNA levels for CLN3 are highest in gastrointestinal tissue and are also high in glandular/secretory tissue, whereas mRNA levels for CLN1 and CLN2 do not appear to be preferentially elevated in any tissue type. The significance of extraneural expression of CLN3 is reviewed in the context of the function of the protein. Show less
no PDF DOI: 10.1006/mgme.2000.3056
CLN3
S Chattopadhyay, N E Muzaffar, F Sherman +1 more · 2000 · Journal of bacteriology · added 2026-04-24
The BTN1 gene product of the yeast Saccharomyces cerevisiae is 39% identical and 59% similar to human CLN3, which is associated with the neurodegenerative disorder Batten disease. Furthermore, btn1-De Show more
The BTN1 gene product of the yeast Saccharomyces cerevisiae is 39% identical and 59% similar to human CLN3, which is associated with the neurodegenerative disorder Batten disease. Furthermore, btn1-Delta strains have an elevated activity of the plasma membrane H(+)-ATPase due to an abnormally high vacuolar acidity during the early phase of growth. Previously, DNA microarray analysis revealed that btn1-Delta strains compensate for the altered plasma membrane H(+)-ATPase activity and vacuolar pH by elevating the expression of the two genes HSP30 and BTN2. We now show that deletion of either HSP30 or BTN2 in either BTN1(+) or btn1-Delta strains does not alter vacuolar pH but does lead to an increased activity of the vacuolar H(+)-ATPase. Deletion of BTN1, BTN2, or HSP30 does not alter cytosolic pH but diminishes pH buffering capacity and causes poor growth at low pH in a medium containing sorbic acid, a condition known to result in disturbed intracellular pH homeostasis. Btn2p was localized to the cytosol, suggesting a role in mediating pH homeostasis between the vacuole and plasma membrane H(+)-ATPase. Increased expression of HSP30 and BTN2 in btn1-Delta strains and diminished growth of btn1-Delta, hsp30-Delta, and btn2-Delta strains at low pH reinforce our view that altered pH homeostasis is the underlying cause of Batten disease. Show less
no PDF DOI: 10.1128/JB.182.22.6418-6423.2000
CLN3